Symbol="IMAB"
AssetType="Common Stock"
Name="I-Mab"
Description="I-Mab, a clinical-stage biopharmaceutical company, discovers, develops and markets biologics to treat cancer and autoimmune disorders. The company is headquartered in Shanghai, the People's Republic of China."
CIK="1778016"
Exchange="NASDAQ"
Currency="USD"
Country="China"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="SUITE 802, WEST TOWER, OMNLVISION, 88 SHANGKE ROAD, PUDONG DISTRICT, SHANGHAI, CHINA"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="231128000"
EBITDA="-1859417984"
PERatio="None"
PEGRatio="None"
BookValue="36.25"
DividendPerShare="0"
DividendYield="0"
EPS="-3.91"
RevenuePerShareTTM="-2.685"
ProfitMargin="0"
OperatingMarginTTM="8.46"
ReturnOnAssetsTTM="-0.242"
ReturnOnEquityTTM="-0.637"
RevenueTTM="-221563008"
GrossProfitTTM="41594000"
DilutedEPSTTM="-3.91"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="1.917"
AnalystTargetPrice="34.5"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="2.545"
PriceToBookRatio="0.587"
EVToRevenue="0.439"
EVToEBITDA="0.101"
Beta="0.939"
num_52WeekHigh="10.82"
num_52WeekLow="2.61"
num_50DayMovingAverage="3.08"
num_200DayMovingAverage="3.93"
SharesOutstanding="83099000"
DividendDate="None"
ExDividendDate="None"
symbol="IMAB"
open="2.77"
high="2.86"
low="2.72"
price="2.77"
volume="383828.00"
latest_trading_day="2023-07-11"
previous_close="2.76"
change="0.01"
change_percent="0.3623%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="66"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="34"
Volume_recent_avg="327961"
Change_recent_avg="-0.01"
Delta_recent_avg="0.23"
Variance_recent_avg="0.12"
Change_ratio_recent_avg="-0.45"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="34"
Aroon_momentum_negative="66"
image_negative_thumbnail_id_1="1162"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0196.jpeg"
image_negative_thumbnail_id_2="127"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0049.jpeg"
image_neutral_thumbnail_id_1="552"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0047.jpeg"
image_neutral_thumbnail_id_2="521"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0078.jpeg"
image_positive_thumbnail_id_1="988"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0150.jpeg"
image_positive_thumbnail_id_2="973"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0135.jpeg"
image_professor_thumbnail_id_1="1172"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0006.jpeg"
image_professor_thumbnail_id_2="1175"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0009.jpeg"
